Clinical Trial Update: Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intermittent docetaxel in combination with erlotinib (Tarceva) for metastatic non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Tarceva (erlotinib)

Snippet

Sponsor: Hellenic Cooperative Oncology Group | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED